Collaborative arrangements - Summary of Revenue Recognized or Expense Incurred for Joint Ide-cel Development Efforts Related to Combined Unit of Accounting for its License and Vector Manufacturing of Ide-cel (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense	$ (154,478)	$ (154,123)
Bristol-Myers Squibb | U.S. | Ide-cel Research and Development Services | License and Manufacturing Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense	(16,825)	(5,080)
Bristol-Myers Squibb | Outside of U.S. | Ide-cel License and Manufacturing Services | License and Manufacturing Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 5,104	$ 13,970